VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viking Therapeutics Inc (VKTX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has promising developments in its pipeline, such as the Phase 3 trial for VK2735, the lack of revenue generation, recent pre-market price decline, and neutral technical indicators suggest waiting for more clarity on clinical trial results or a better entry point.
The MACD is negative and contracting (-0.201), RSI is neutral at 58.307, and moving averages are converging. The stock is trading near its pivot level of 34.301, with resistance at 36.597 and support at 32.006. Overall, the technical indicators do not suggest a strong buy signal.
Completion of enrollment for Phase 3 trial of VK2735, targeting obesity and metabolic disorders.
Speculation of a potential buyout and improved retail investor sentiment.
Expected clinical trial results in Q3 2026, which could act as a major catalyst.
The company has yet to generate revenue and reported a significant net loss of $359.6 million in
Pre-market price decline of -1.05% and neutral insider and hedge fund trading trends.
Increasing competition in the anti-obesity drug market, which could impact the company's market share.
In Q4 2025, Viking Therapeutics reported no revenue and a net loss of $157.66 million, an improvement of 345.16% YoY. EPS improved to -1.38, up 331.25% YoY. Despite these improvements, the company remains unprofitable with no revenue generation.
Morgan Stanley analyst Michael Ulz lowered the price target to $99 from $102 but maintained an Overweight rating, indicating long-term optimism despite a slight adjustment in expectations.
